Inflammatory cytokine pathways in ocular surface tissues

Inflammatory cytokine pathways in ocular surface tissues represent a complex network of signaling cascades that drive the pathogenesis of various ocular surface diseases, most notably dry eye disease (DED) [1.1.1, 1.2.2]. These pathways are typically triggered by environmental stressors, tear hyperosmolarity, and desiccation, which activate innate immune responses in corneal and conjunctival epithelial cells [1.2.1, 1.2.3]. Key signaling nodes include the mitogen-activated protein kinase (MAPK) and nuclear factor-kappaB (NF-κB) pathways, which promote the production of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α [1.1.1, 1.2.4]. This initial response recruits and activates T-helper cells (specifically Th1 and Th17), which further amplify the inflammation by secreting IFN-γ and IL-17, creating a self-perpetuating "vicious cycle" of ocular surface damage and chronic inflammation [1.2.2, 1.2.5]. Therapeutic strategies targeting these pathways include immunomodulators like cyclosporine and lifitegrast, as well as corticosteroids, which aim to break this cycle by inhibiting T-cell activation, cytokine production, or leukocyte adhesion [1.1.2, 1.1.5].

Other names

Ocular surface inflammatory cascadeOcular surface cytokine signalingPro-inflammatory cytokine pathways in dry eyeOcular surface inflammation (OSI) pathways

Inhibition of calcineurin to block T-cell activation and IL-2 production; antagonism of LFA-1 to prevent interaction with ICAM-1 and leukocyte migration; inhibition of NF-κB and MAPK signaling to reduce pro-inflammatory cytokine transcription; and suppression of matrix metalloproteinases (MMPs) to preserve corneal integrity [1.1.1, 1.1.2, 1.1.5, 1.2.4].